chevron_leftBack
As of 24 April 2025, Addex Therapeutics Ltd. has a market cap of $6.33M USD, ranking #34849 globally and #229 in Switzerland. It ranks #3498 in the Healthcare sector, and #1163 in the Biotechnology industry.
Key Stats
Market Cap
$6.33MUSD
5.23M CHF
Enterprise Value
$2.32MUSD
1.93M CHF
Revenue (TTM)
$717.23KUSD
592.36K CHF
EBITDA (TTM)
-$13.13MUSD
-10.89M CHF
Net Income (TTM)
$6.54MUSD
5.4M CHF
Profit Margin
912%
PE Ratio
1.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Timothy Dyer
open_in_new
Employees
23
Founded
2002
Website
addextherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -5.3% | 0.8% | -12% | -20% | -40% | -63% |
Upcoming Earnings
Earnings Date
Mon, May 19
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ADXN
Addex Therapeutics Ltd
ISIN: CH0029850754
Shares Out.:
Shares Outstanding:
98.323M1
Shares Float:
82.011M2
|
0.0504 CHF | |
|
NASDAQ
MIC: XNAS
|
ADXN
Addex Therapeutics Ltd ADR
ISIN: US00654J2069
Shares Out.:
Shares Outstanding:
819.36K1
Shares Float:
819.119K2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
7.60 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Addex Therapeutics Ltd.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
